Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 23CNS 1

Conditions

Brain Neoplasms 31Glioblastoma 24Gliosarcoma 22Carcinoma, Non-Small-Cell Lung 16Glioma 12Astrocytoma 11Central Nervous System Neoplasms 9Oligodendroglioma 8Lung Neoplasms 6Squamous Cell Carcinoma of Head and Neck 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Medulloblastoma 3Esthesioneuroblastoma, Olfactory 3Colonic Neoplasms 3Osteosarcoma 2Neuroendocrine Tumors 2Neuroblastoma 2Neoplasms 2Familial ependymoma 2Esophageal Neoplasms 2Ependymoma 2Diffuse Intrinsic Pontine Glioma 2Choroid Plexus Neoplasms 2Carcinoma, Hepatocellular 2Carcinoid Tumor 2Anus Neoplasms 2Wilms Tumor 1

Interventions

fludarabine phosphate 1anlotinib 1aflutinib 1Temozolomide 1Specimen Handling 1Radiotherapy 1Platinum 1Pemetrexed 1Magnetic Resonance Spectroscopy 1Interleukin-13 1Fluorodeoxyglucose F18 1Erlotinib Hydrochloride 1Cyclophosphamide 1Cisplatin 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × Erlotinib Hydrochloride × CNS × Clear all
NCT01578668 2015-01-26

Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

Guangzhou Medical University

Phase 2 Completed
69 enrolled
CNSThoracic

Adenocarcinoma of Lung, Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡